SQZ Biotech is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using our proprietary technology, we have the unique ability to engineer almost any cell type and deliver multiple materials, potentially resulting in powerful, multifunctional cell therapies for a range of diseases.
We are creating cell therapies that we believe will be well-tolerated and able to provide therapeutic benefit for patients and potentially improve the patient experience, with accelerated production timelines under 24 hours and the elimination of difficult pre-conditioning and lengthy hospital stays.
Our goal is to establish a new paradigm for cell therapies. Our initial therapeutic applications leverage our ability to generate target-specific immune responses, both in activation for the treatment of solid tumors and immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases. Our first clinical trial, SQZ-PBMC-HPV-001, is currently enrolling patients with HPV16+ advanced or metastatic tumors.